Italia Markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
58,10-0,71 (-1,21%)
Alla chiusura: 04:00PM EDT
58,09 -0,01 (-0,02%)
Dopo ore: 06:48PM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700

Impiegati a tempo pieno2.324

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Herve HoppenotCEO & Chairman2,89MN/D1960
Ms. Christiana Stamoulis MBAExec. VP & CFO1,16MN/D1971
Ms. Maria E. Pasquale J.D.Exec. VP, Gen. Counsel & Corp. Sec.1,02MN/D1966
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.Exec. VP & GM of North America996,28k545,65k1958
Dr. Steven H. Stein M.D.Exec. VP & Chief Medical Officer1,22MN/D1967
Dr. Pablo J. Cagnoni M.D., Ph.D.Pres and Head of R&DN/DN/D1963
Mr. Thomas TrayVP of Fin., Chief Accounting Officer & ControllerN/DN/D1978
Mr. Michael James MorrisseyExec. VP & Head of Global Technical OperationsN/DN/D1964
Ms. Christine ChiouHead of Investor RelationsN/DN/DN/D
Ms. Pamela M. MurphyVP of Investor Relations & Corp. CommunicationsN/DN/D1951
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Governance aziendale

L'ISS Governance QualityScore di Incyte Corporation al 1 settembre 2023 è 8. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 6; diritti degli azionisti: 6; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.